|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effectiveness of hepatitis B virus vaccination program in Egypt:Multicenter national project显示文摘AIM:To assess the effectiveness of hepatitis B virus(HBV) vaccination program among fully vaccinated children.METHODS:A national community based crosssectional study was carried out in 6 governorates representing Egypt. A total of 3600 children aged from 9 mo to 16 years who were fully vaccinated with HBV vaccine during infancy were recruited. Face to face interviews were carried out and sera were evaluated for hepatitis B surface antigen(HBsA g),anti-HBV core antibodies(total) and quantitative detection of hepatitis B surface antibody using enzyme linked immunoassays techniques. Samples positive to HBs Ag/anti-HBV core antibodies were subjected to quantitative HBV-DNA detection by real time polymerase chain reaction with 3.8 IU/L detection limit. RESULTS:Sero-protection was detected among 2059 children(57.2%) with geometric mean titers 75.4 ± 3.6 IU/L compared to 3.1 ± 2.1 IU/L among nonseroprotected children. Multivariate logistic analysis revealed that older age and female gender were the significant predicting variables for having non seroprotective level,with adjusted odds ratio 3.3,9.1and 14.2 among children aged 5 to < 10,10 to < 15 and ≥ 15 years respectively compared to those < 5 years and 1.1 among girls compared to boys with P < 0.01. HBs Ag was positive in 0.11% and breakthrough infection was 0.36% and 0.39% depending on positivity of anti-HBc and DNA detection respectively. The prevalence of HBV infection was significantly higher among children aged ≥ 7 years(0.59%) compared to 0.07% among younger children with odds ratio equal to 8.4(95%CI:1.1-64.2) and P < 0.01.The prevalence was higher among girls(0.48%) than boys(0.29%) with P > 0.05. C ON C LU S I ON :T he E gy pt ian c ompuls or y H B V vaccination program provides adequate protection. Occult HBV infection exists among apparently healthy vaccinated children. Adherence to infection control measures is mandatory. | Iman I Salama Samia M Sami Zeinab Nabil Ahmed Said Manal H El-Sayed Lobna A El Etreby Thanaa M Rabah Dalia M Elmosalami Amany T Abdel Hamid Somaia I Salama Aida M Abdel Mohsen Hanaa M Emam Safaa M Elserougy Amal I Hassanain Naglaa F Abd Alhalim Fatma A Shaaban Samia A Hemeda Nihad A Ibrahim Ammal M Metwally | 2015 | World Journal of Hepatology2015,7,22: | 2 |
| 2 | Tuning the selectivity of metha- nol-to-hydrocarbons conversion on H-ZSM-5 by co-pro- cessing oletin or aromatic compounds 显示文摘 | SAMIA I ADITYA B | 2012 | Journal of Ca- talysis2012,290,: | 1 |
| 3 | A descriptor for the relative propagation of the aromatic- and olefin- based cycles in methanol-to-hydrocarbons conversion on H-ZSM-5 显示文摘 | SAMIA I RACHIT K ANDRE M | 2013 | Journal of Catalysis2013,303,: | 1 |
| 4 | Interaction between angiotensin - conwerting enzyme and catechol -O- methyltransferase genotypes in schizephrenics with poor response to conwentional neuroleptics 显示文摘 | Sria I Ollia K Samia A | 2003 | European Neuropsy chopharmacology2003,13,2: | 1 |
| 5 | Content of antinut-ritional factors and HCl-extractability of minerals from white bean(Phaseolus vulgaris) cultivars, influence of soaking andor cooking显示文摘 | HAGIR B E SAMIA M A WISAL H I | 2007 | Food Chemistry2007,,100: | 1 |
| 6 | A descriptor for the relative propagation of the aromatic- and olefm-based cycles in methanol-to-hydrocarbons conversion on HZSM-5显示文摘 | Samia I Rachit K Andre M | 2013 | Journal of Catalysis2013,303,: | 1 |
| 7 | Mechanism of the catalytic conversion of methanol to hydrocarbons显示文摘 | Samia I Aditya B | 2013 | ACS Catal2013,3,: | 1 |
| 8 | Influence of inoculation with plant growth promoting rhizobaeteria (PGPR) on tomato plant growth and nematode reproduction under greenhouse eonditions 显示文摘 | Omar A Almagbrahi Samia I | 2013 | Saudi Journal of Biological Seienees2013,,20: | 1 |
| 9 | Changes in rainfall partitioning caused by the replacement of native dry forests of Lithraea molleoides by exotic plantations of Pinus elliottii in the dry Chaco mountain forests, central Argentina显示文摘The replacement of native dry forests by commercial(exotic)tree plantations could generate changes in rainfall partitioning,which further affects the water cycle.In this study,we determined(i)the rainfall partitioning into interception,throughfall and stemflow,(ii)the role of rainfall event size on rainfall partitioning,(iii)the pH of water channelized as throughfall and stemflow,and(iv)the runoff in Lithraea molleoides(a native species)and Pinus elliottii(an exotic species)stands in the dry Chaco mountain forests,central Argentina.On average,interception,throughfall and stemflow accounted for 19.3%,79.5%and 1.2%of the gross rainfall in L.molleoides stand,and 32.6%,66.7%and 0.7%of the gross rainfall in P.elliottii stand,respectively.Amounts of interception,throughfall and stemflow presented positive linear relationships with the increment of rainfall event size for both tree species(P<0.01 in all cases).Percentages of interception,throughfall and stemflow were all related to the increment of rainfall event size,showing different patterns.With increasing rainfall event size,interception exponentially decreased,throughfall asymptotically increased and stemflow linearly increased.Both P.elliottii and L.molleoides stands presented significant differences in the pH values of water channelized as throughfall(6.3 vs.6.7,respectively;P<0.01)and stemflow(4.5 vs.5.8,respectively;P<0.01).Runoff occupied only 0.3%of the gross rainfall in P.elliottii stand and was zero in L.molleoides stand.Our results showed that the native species L.molleoides presented 13.6%more water reaching the topsoil(i.e.,net rainfall;net rainfall=gross rainfall-interception-runoff)than the exotic species P.elliottii.This study improves our understanding of the effects of native vegetation replacement on the local water balance in the dry forest ecosystems. | Samia S CORTÉS Juan I WHITWORTH-HULSE Eduardo L PIOVANO Diego E GURVICH Patricio N MAGLIANO | 2020 | Journal of Arid Land2020,12,5: | 0 |
| 10 | Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection显示文摘Hepatitis C virus(HCV)is a common cause of liver disease and is associated with various extrahepatic manifestations(EHMs).This mini-review outlines the currently available treatments for HCV infection and their prognostic effect on hepatic manifestations and EHMs.Direct-acting antiviral(DAA)regimens are considered pan-genotypic as they achieve a sustained virological response(SVR)>85%after 12 wk through all the major HCV genotypes,with high percentages of SVR even in advanced fibrosis and cirrhosis.The risk factors for DAA failure include old males,cirrhosis,and the presence of resistance-associated substitutions(RAS)in the region targeted by the received DAAs.The effectiveness of DAA regimens is reduced in HCV genotype 3 with baseline RAS like A30K,Y93H,and P53del.Moreover,the European Association for the Study of the Liver recommended the identification of baseline RAS for HCV genotype 1a.The higher rate of hepatocellular carcinoma(HCC)after DAA therapy may be related to the fact that DAA regimens are offered to patients with advanced liver fibrosis and cirrhosis,where interferon was contraindicated to those patients.The change in the growth of pre-existing subclinical,undetectable HCC upon DAA treatment might be also a cause.Furthermore,after DAA therapy,the T cell-dependent immune response is much weaker upon HCV clearance,and the down-regulation of TNF-αor the elevated neutrophil to lymphocyte ratio might increase the risk of HCC.DAAs can result in reactivation of hepatitis B virus(HBV)in HCV coinfected patients.DAAs are effective in treating HCV-associated mixed cryoglobulinemia,with clinical and immunological responses,and have rapid and high effectiveness in thrombocytopenia.DAAs improve insulin resistance in 90%of patients,increase glomerular filtration rate,and decrease proteinuria,hematuria and articular manifestations.HCV clearance by DAAs allows a significant improvement in atherosclerosis and metabolic and immunological conditions,with a reduction of major cardiovascular events.They also improve physical function,fatigue,cognitive impairment,and quality of life.Early therapeutic approach with DAAs is recommended as it cure many of the EHMs that are still in a reversible stage and can prevent others that can develop due to delayed treatment. | Iman Ibrahim Salama Hala M Raslan Ghada A Abdel-Latif Somaia I Salama Samia M Sami Fatma A Shaaban Aida M Abdelmohsen Walaa A Fouad | 2022 | World Journal of Hepatology2022,14,6: | 0 |
| 11 | Current and novel modalities for management of chronic hepatitis B infection显示文摘Over 296 million people are estimated to have chronic hepatitis B viral infection(CHB),and it poses unique challenges for elimination.CHB is the result of hepatitis B virus(HBV)-specific immune tolerance and the presence of covalently closed circular DNA as mini chromosome inside the nucleus and the integrated HBV.Serum hepatitis B core-related antigen is the best surrogate marker for intrahepatic covalently closed circular DNA.Functional HBV“cure”is the durable loss of hepatitis B surface antigen(HBsAg),with or without HBsAg seroconversion and undetectable serum HBV DNA after completing a course of treatment.The currently approved therapies are nucleos(t)ide analogues,interferon-alpha,and pegylated-interferon.With these therapies,functional cure can be achieved in<10%of CHB patients.Any variation to HBV or the host immune system that disrupts the interaction between them can lead to reactivation of HBV.Novel therapies may allow efficient control of CHB.They include direct acting antivirals and immunomodulators.Reduction of the viral antigen load is a crucial factor for success of immune-based therapies.Immunomodulatory therapy may lead to modulation of the host immune system.It may enhance/restore innate immunity against HBV(as toll-like-receptors and cytosolic retinoic acid inducible geneⅠagonist).Others may induce adaptive immunity as checkpoint inhibitors,therapeutic HBV vaccines including protein(HBsAg/pre S and hepatitis B core antigen),monoclonal or bispecific antibodies and genetically engineered T cells to generate chimeric antigen receptor-T or T-cell receptor-T cells and HBV-specific T cells to restore T cell function to efficiently clear HBV.Combined therapy may successfully overcome immune tolerance and lead to HBV control and cure.Immunotherapeutic approaches carry the risk of overshooting immune responses causing uncontrolled liver damage.The safety of any new curative therapies should be measured in relation to the excellent safety of currently approved nucleos(t)ide analogues.Development of novel antiviral and immune modulatory therapies should be associated with new diagnostic assays used to evaluate the effectiveness or to predict response. | Iman Ibrahim Salama Samia M Sami Somaia I Salama Ghada A Abdel-Latif Fatma A Shaaban Walaa A Fouad Aida M Abdelmohsen Hala M Raslan | 2023 | World Journal of Hepatology2023,15,5: | 0 |